• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Insurers, States Strike Hepatitis C Deals

Article

Insurers and state Medicaid agencies have been eager to strike a deal with pharmaceutical companies to secure discounts on pricey hepatitis C drugs.

Both insurers and state Medicaid agencies are working to secure discounts on pricey hepatitis C drugs.

Insurers and states alike have been eager to strike a deal with the pharmaceutical companies, especially considering

the backlash Gilead's Sovaldi received last year after the company placed a $100,000 per person price tag on the drug. Harvoni is Gilead's follow-up to Sovaldi.

Missouri signed a deal with AbbVie this week to make Viekira Park the preferred drug covered by the state's Medicaid program, noted the Wall Street Journal

. The drug will replace Sovaldi. AbbVie will "provide a rebate to states participating in the consortium."

Read more: http://bit.ly/15UL9hm

Source: Fierce Health Payer

Related Videos
Video 15 - "Ensuring Fair Cardiovascular Care for All: Concluding Perspectives on Disparities and Inclusion"
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP
Ryan Stice, PharmD
Raajit Rampal, MD, PhD, screenshot
Leslie Fish, PharmD.
Ronesh Sinha, MD
Adam Colborn, JD
Beau Raymond, MD
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.